Synthesis, in vitro and in vivo evaluation of $^{11}$C-O-methylated arylpiperazines as potential serotonin 1A (5-HT$_{1A}$) receptor antagonist radiotracers

Vidya Narayanaswami, Junchao Tong, Ferdinando Fiorino, Beatrice Severino, Rosa Sparaco, Elisa Magli, Flavia Giordano, Peter M. Bloomfield, Jaya Prabhakaran, J. John Mann, Neil Vasdev and J. S. Dileep Kumar

**Abstract**

**Background:** Serotonin 1A (5-HT$_{1A}$) receptors are implicated in the pathogenesis of several psychiatric and neurodegenerative disorders motivating the development of suitable radiotracers for in vivo positron emission tomography (PET) neuroimaging. The gold standard PET imaging agent for this target is $[^{11}\text{C}]$WAY-100635, labeled via a technically challenging multi-step reaction that has limited its widespread use. While several antagonist and agonist-based PET radiotracers for 5-HT$_{1A}$ receptors have been developed, their clinical translation has been hindered by methodological challenges and/or non-specific binding. As a result, there is continued interest in the development of new and more selective 5-HT$_{1A}$ PET tracers having a relatively easier and reliable radiosynthesis process for routine production and with favorable metabolism to facilitate tracer-kinetic modeling. The purpose of the current study was to develop and characterize a radioligand with suitable characteristics for imaging 5-HT$_{1A}$ receptors in the brain. The current study reports the in vitro characterization and radiosyntheses of three candidate 5-HT$_{1A}$ receptor antagonists, DF-100 (1), DF-300 (2) and DF-400 (3), to explore their suitability as potential PET radiotracers.

(Continued on next page)
Results: Syntheses of 1–3 and corresponding precursors for radiolabeling were achieved from isonicotinic, picolinic acid or picolino nitrile. In vitro binding studies demonstrated nanomolar affinity of the compounds for 5-HT\textsubscript{1A} receptors. Binding of 1–3 for other biogenic amines, neurotransmitter receptors, and transporters was negligible with the exception of moderate affinities for \(\alpha\textsubscript{1}\)-adrenergic receptors (4–6-fold less potent than that for 5-HT\textsubscript{1A} receptor). Radioligands \([\text{11C}]\textsubscript{1}–\textsubscript{3}\) were efficiently prepared by \([\text{11C}]\textsubscript{C}\textsubscript{1}-O\textsubscript{methylation of the corresponding phenolic precursor in non-decay corrected radiochemical yields of 7–11\% with > 99\% chemical and radiochemical purities. Dynamic PET studies in rats demonstrated negligible brain uptake of \([\text{11C}]\textsubscript{1}\) and \([\text{11C}]\textsubscript{2}\). In contrast, significant brain uptake of \([\text{11C}]\textsubscript{3}\) was observed with an early peak SUV of 4–5. However, \([\text{11C}]\textsubscript{3}\) displayed significant off-target binding attributed to \(\alpha\textsubscript{1}\)-adrenergic receptors based on regional distribution (thalamus>hippocampus) and blocking studies.

Conclusion: Despite efficient radiolabeling, results from PET imaging experiments limit the application of \([\text{11C}]\textsubscript{3}\) for in vivo quantification of 5-HT\textsubscript{1A} receptors. Nevertheless, derivatives of compound 3 may provide a scaffold for alternative PET radiotracers with improved selectivity for 5-HT\textsubscript{1A} receptors or \(\alpha\textsubscript{1}\)-adrenergic receptors.

Keywords: \(\alpha\textsubscript{1}\)-adrenergic receptor, Carbon-11, 5-HT\textsubscript{1A} receptor, Serotonin, PET

Introduction
5-Hydroxytryptamine or serotonin (5-HT) is a major neurotransmitter and neuromodulator at central and peripheral sites (Barnes and Sharp 1999). Physiologically, 5-HT is crucial in the control of sleep, wakefulness, mood, feeding behavior, learning and memory, decision-making and the control of sensory transmission. Disruption in 5-HT neurotransmission and/or 5-HT receptor function has been implicated in the pathophysiology of several neuropsychiatric and neurodegenerative disorders that include: major depression, anxiety disorders, schizophrenia, sleep disorders, Alzheimer’s disease, Parkinson’s disease and epilepsy (Burnet et al. 1997; Merlet et al. 2004; Sullivan et al. 2005; Schmitt et al. 2006; Kepe et al. 2006; Ballanger et al., 2012; Michelsen et al. 2008; Pagano and Politis 2018). To date, fourteen 5-HT receptor subtypes have been identified and have been divided into seven classes, 5-HT\textsubscript{1} to 5-HT\textsubscript{7}, according to their structural and functional characteristics. The 5-HT\textsubscript{1A} subtype is amongst the best characterized. The 5-HT\textsubscript{1A} receptor is a G-protein-coupled receptor concentrated in cortical and limbic regions that receive serotonergic input from the raphe nuclei such as the frontal cortex, amygdala, and hippocampus (Weissmann-Nanopoulos et al. 1985; Hoyer et al. 1986; Radja et al. 1992). The 5-HT\textsubscript{1A} receptor serves predominantly as an autoreceptor that controls 5-HT release from serotonin neurons in the raphe nuclei by hyper-polarizing the neuron after serotonin release from recurrent short fibers that terminate on the soma and dendrites of serotonin neurons. Thus, this receptor regulates 5-HT neurotransmission to its projection areas, and is expressed by target neurons as a postsynaptic receptor in frontal and limbic projection regions (Weissmann-Nanopoulos et al. 1985; Radja et al. 1992).

Clinical relevance of 5-HT\textsubscript{1A} receptors in the pathogenesis of several psychiatric and neurodegenerative disorders has encouraged significant efforts in developing both carbon-11 and fluorine-18 labeled radiotracers for in vivo positron emission tomography (PET) neuroimaging studies to investigate alterations of 5-HT\textsubscript{1A} receptors in
human brain. These imaging approaches may not only provide insight into disease diagnosis, subtypes and its progression, but also provide a biomarker of disease response, and permit receptor occupancy studies of drugs. Over the past three decades, several 5-HT\textsubscript{1A} receptor antagonist- and agonist-based PET or SPECT radioligands have been evaluated for imaging purposes (Kumar and Mann 2014). Currently available PET radiotracers for 5-HT\textsubscript{1A} exhibit structural similarity to the 5-HT\textsubscript{1A} antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide (WAY100635). At present, [carbonyl-\textsuperscript{11}C]WAY100635 (Osman et al. 1996; Krasikova et al. 2009), [\textsuperscript{11}C]DWAY (Pike et al. 1998; Andree et al. 2002), [\textsuperscript{18}F]FCWAY (Choi et al. 2014), and [\textsuperscript{18}F]MPPF (Shiue et al. 1997) are the reported antagonist PET ligands for the quantification of 5-HT\textsubscript{1A} receptors in humans. [carbonyl-\textsuperscript{11}C]WAY100635, with significant improvements over its predecessor, [O-methyl-\textsuperscript{11}C]WAY100635, on brain-penetrating metabolites (Osman et al. 1996), is still the gold standard radiotracer for 5-HT\textsubscript{1A} brain imaging in humans and has the highest specific to non-specific binding ratios among the 5-HT\textsubscript{1A} tracers. There are discrepant reports about the non-displaceable binding potential (BP) of [carbonyl-\textsuperscript{11}C]WAY100635 in patients with major depressive disorder as only marginal non-specific binding is observed in the cerebellar vermis (Drevets et al. 1999; Sargent et al. 2000; Meltzer et al. 2004; Parsey et al. 2006; Hirvonen et al. 2008). Due to the low non-specific binding in cerebellum, the BP, based on measurement of the free fraction of radioligand in plasma, can only be accurately obtained with full arterial input function and can lead to variability in binding outcome measurements. The challenging kinetic measurements of [carbonyl-\textsuperscript{11}C]WAY100635 coupled with rapid metabolism, low free fraction, complicated radiosynthesis and low yield, and the short half-life of carbon-11 have been ongoing motivations to develop alternative PET radiotracers for imaging the 5-HT\textsubscript{1A} receptors.

[\textsuperscript{18}F]FCWAY, the fluoro-analogue of WAY100635 has been tested as an alternative; however, potential in vivo defluorination is the major drawback of this tracer (Choi et al. 2014). While [\textsuperscript{18}F]MPPF, the fluoroaryl analogue of WAY100635, exhibited optimum sensitivity to measure intra-synaptic 5-HT levels in vivo in rodents, studies in awake monkeys and human subjects did not show such effect. Moreover, [\textsuperscript{18}F]MPPF is a P-glycoprotein substrate that limits further utility in clinical application (Shiue et al. 1997; Aznavour and Zimmer 2007). In addition to nanomolar affinity of [\textsuperscript{11}C](R)-WAY, the reverse amide of WAY100635, to 5-HT\textsubscript{1A} receptors (Ki = 0.6 nM), this radiotracer also possesses significant affinity to 5-HT\textsubscript{2B} receptors (Ki = 7.2 nM), alpha-1 (\(\alpha_1\)) adrenergic receptors (Ki = 10.35 nM), and dopaminergic receptors (D2, Ki = 34.5 nM; D3, Ki = 5.1 nM; and D4, Ki = 15.6 nM) (Yasuno et al. 2006). Moreover, the presence of radioactive metabolites in the brain and its binding to P-glycoprotein restricts its clinical translation (Zhang et al. 2007). [\textsuperscript{18}F](trans)-MeFWAY has been successfully evaluated in human subjects (Mukherjee et al. 2016). However, kinetic analyses with arterial input functions have to be performed for the full quantification of this radiotracer.

Development of agonist-based 5-HT\textsubscript{1A} receptors has also faced certain challenges primarily due to a lack of detectable specific binding. Among these, [\textsuperscript{11}C]CUMI-101 or [\textsuperscript{14}C]MMP have been investigated in non-human primates and human subjects (Kumar et al. 2007; Milak et al. 2010). Pre-treatment with the \(\alpha_1\)-adrenergic receptor antagonist, prazosin, demonstrated partial displacement of [\textsuperscript{11}C]CUMI-101
binding in the thalamus and cerebellum of rats and monkeys indicating moderate affinity of CUMI-101 to \( \alpha_1 \)-adrenergic receptor (Shrestha et al. 2014). However, such effect was not found in in vitro autoradiography studies in non-human primate and human brain sections with \([^{3}\text{H}]\)CUMI-101 (Kumar et al. 2013). On the other hand, despite specific in vitro binding of \([^{11}\text{C}]\)MPT in 5-HT\(_{1A}\) receptor-rich regions, the slow washout in baboons complicates the quantification of binding parameters (Kumar et al. 2006).

Given the aforementioned limitations that restrict the clinical utility of currently available 5-HT\(_{1A}\) receptor radiotracers, there is continued interest in the development of new and more selective 5-HT\(_{1A}\) PET tracers having a relatively easier and reliable radiosynthesis process for routine production and with favorable metabolism in order to facilitate tracer-kinetic modeling. To that end, the purpose of the current study was to develop and characterize a radioligand with suitable characteristics for imaging 5-HT\(_{1A}\) receptors in the brain. Most 5-HT\(_{1A}\) receptor PET ligands developed to date are analogues of WAY100635 or the arylpiperazine scaffold and have been achieved with limited success (Kumar and Mann 2014). We sought to develop PET tracers of WAY100635 analogues without the cyclohexane group in view of enhancing 5-HT\(_{1A}\) receptor selectivity and improving brain uptake and non-specific binding by lowering the lipophilicity. Among the reported arylpiperazine analogues; isonicotinamide, picolinamid, picolinamide bearing a 2-carbon (ethyl) linker to the amide with a \( O \)-methoxy phenyl group and, \( N \)-cyanonicotimamide bearing three carbon (propyl) linkers showed high affinity to 5-HT\(_{1A}\) and 5-HT\(_{2A}\) receptors (Fiorino et al. 2012; Fiorino et al. 2016; Fiorino et al. 2017). The binding assays for these ligands were performed using 3 concentrations with hill co-efficients less than one; however, receptor selectivity data has not been previously reported. We herein present the detailed in vitro binding characterization of these three high affinity 5-HT\(_{1A}\) receptor antagonists amenable for radiolabeling by standard \(^{11}\text{C}\)-\( O \)-methylation reactions. We further explore the feasibility of the resultant \(^{11}\text{C}\)-labeled radioligands to image 5-HT\(_{1A}\) receptors by conducting preliminary PET/MR imaging in rodents.

**Methods**

**Chemistry and in vitro pharmacological characterization of novel 5-HT\(_{1A}\) receptor ligands; DF-100 (1), DF-300 (2) and DF-400 (3)**

Syntheses of compounds 1–3 were achieved using previously established procedures (Fiorino et al. 2012, Fiorino et al. 2016, Fiorino et al. 2017). The synthesis of desmethyl-DF-100, the radiolabeling precursor, was achieved from 2-cyanopyridine in three steps. Methyl-\( N \)-cyano-2-pyridinecarboximidate obtained by reacting 2-cyanopyridine with cyanamide was coupled with 3-bromopropylamine and subsequent condensation of resulting cyanopicolinamidine with 2-hydroxyphenylpiperazine afforded desmethyl-DF-100. Synthesis of desmethyl-DF-300 and desmethyl-DF-400 were achieved from picolinic acid or isonicotinic acid by reacting with 2-chloroethanamine followed by condensation with 2-hydroxyphenyl-piperazine. Details of the chemical syntheses scheme is provided in the supplementary information.

Binding affinity (\( K_i \)) of compounds 1–3 at 5-HT\(_{1A}\) receptors were determined by competition binding studies with \([^{3}\text{H}]\)WAY100635 employing 12 concentrations of the
compounds (10 μM to 1 pM) in triplicate measurements and using 8-hydroxy-2-(di-n-propilamino)tetralin (8-OH-DPAT, a 5-HT₁A agonist) as a reference standard in stable chicken hamster ovary cells expressing 5-HT₁A receptor (National Institute of Mental Health-Psychoactive Drug Screening Program (NIMH-Psychoactive Drug Screening Program (PDSP)). Cross selectivity for biogenic amines, neurotransmitter receptors, and transporters were determined by radioligand binding assays through NIMH-PDSP using validated and established protocols (NIMH-PDSP Assay Protocol Book Version III, March 2018).

**Radiosyntheses**

Details pertaining to the syntheses of radiolabeling precursors for 1–3 are provided in the supplementary information. Unless otherwise stated, all reagents and solvents used for radiosynthesis were purchased from Sigma Aldrich (St. Louis, Missouri, US) and used without further purification. Quality control high performance liquid chromatography (HPLC) analysis was performed using a high-pressure isocratic pump (LC-20AT; Shimadzu Inc., Kyoto, Japan) and a variable wavelength ultraviolet (UV) detector (λ = 254 nm, SPD-20A, Shimadzu Inc.) in a series with a radioactivity detector (Frisk-tech, Bicron; Torrington, Connecticut, US) connected in series. The system was equipped with a reverse phase analytical HPLC (Luna C-18, 10 μm, 4.6 × 250 mm, Phenomenex; Torrance, California, US) and controlled by PowerChrom chromatography software (eDAQ Pty Ltd.; Colorado Springs, Colorado, US).

*Preparation of [11C]methyl iodide ([11C]CH₃I):* [11C]CH₃I was produced using a previously reported gas-phase iodination method (Larsen et al. 1997). No-carrier-added [11C]carbon dioxide ([11C]CO₂) production was performed using a MC17 cyclotron (Scanditronix; Uppsala, Sweden). The 14N(p, α)¹¹C reaction was employed in a pressurized gas target containing nitrogen and 0.5% oxygen by bombardment with 30 μA proton beam for 30 min (~37 GBq of [11C]CO₂). [11C]CO₂ was delivered from the cyclotron target via a 1/8″ stainless-steel delivery line by nitrogen pressure directly to a column packed with 0.3 g of molecular sieve and 0.2 g of nickel (Shimalite-Ni (reduced), Shimadzu Inc.) where it was trapped at room temperature. The column was then sealed under hydrogen gas and heated to 350 °C for 60 s to reduce the [11C]CO₂ to [11C]CH₄. The [11C]CH₄ was passed through a column of phosphorus pentoxide and trapped on a column of carbosphere cooled to −75 °C (with liquid nitrogen). Gaseous [¹¹C]CH₄ was released by heating the carbosphere column to 80 °C. Once released, the [¹¹C]CH₄ entered a circulation loop, which includes a membrane-based gas pump, a column of iodine at 100 °C, a quartz-glass iodine reactor tube at 740 °C, two adjacent columns of Ascarite, and a column of Porapak Q at room temperature. The gaseous mixture was circulated for 5 min, whereas [¹¹C]CH₃I accumulated on the Porapak column. [¹¹C]CH₃I (15 GBq, 400 mCi) was then released from the Porapak column and delivered directly to the reaction vessel using a control stream of He flow (10 mL/ min) while heating the Porapak column to 190 °C.

*Synthesis of [¹¹C]DF-100 ([¹¹C]1), [¹¹C]DF-300 ([¹¹C]2) and [¹¹C]DF-400 ([¹¹C]3):* [¹¹C]CH₃I was trapped in the reaction mixture containing the corresponding radiolabeling precursor at room temperature. Reaction mixture for respective radiotracer synthesis were as follows: [¹¹C]1: 0.5 mg of desmethyl-DF-100, 3 μL TBAOH (1 M in MeOH), 300 μL DMSO; [¹¹C]2: 0.5 mg of desmethyl-DF-300, 3 μL NaOH (1 M in
H2O), 300 μL DMF; [11C]3: 0.5 mg of desmethyl-DF-400, 3 μL NaOH (1 M in H2O), 300 μL DMF. After the end of radioactivity delivery, the reaction vial was heated at 70 °C for 3 min. The reaction was quenched with 1.0 mL of water and injected onto a HPLC column (Nucleosil C-18 Nautilus. 5 μm, 10 × 250 mm, MACHEREY-NAGEL GmbH & Co; Düren, Germany) for further purification. Radioligands were eluted with following mobile phase composition: [11C]1 and [11C]3: 25:75 CH3CN/0.1 N ammonium formate; [11C]2: 30:70 CH3CN/0.1 N ammonium formate. All three radiotracers were eluted with a flowrate of 5 mL/min. The eluent was monitored by UV (λ = 254 nm) and radioactivity detectors connected in series (Rt [11C]1 = 13 min; Rt [11C]2 = 12 min; Rt [11C]3 = 13.5 min). The product was diluted with 25 mL of sterile water. The diluted HPLC fraction was then loaded on a solid-phase extraction cartridge (SepPak tC18 Plus, Waters; Milford, Massachusetts, US), then washed with 10 mL of sterile water. Radiotracers were recovered in 1.0 mL of dehydrated ethanol for injection, USP, and 10 mL of 0.9% sodium chloride for injection, USP. [11C]1 was obtained in 9% radiochemical yield (RCY) (non-decay corrected) at end-of-synthesis (39 min) based upon [11C]CO2, with > 99% radiochemical purity (RCP) and in a molar activity (Am) of 99 GBq/μmol. [11C]2 was obtained in 7% RCY (non-decay corrected) at end-of-synthesis (37 min) based upon [11C]CO2, with > 99% RCP and in a Am of 81 GBq/μmol. [11C]3 was obtained in 7.5 ± 1.5% (n = 5) RCY (non-decay corrected) at end-of-synthesis (38 min) based upon [11C]CO2, with > 99% RCP and in a Am of 131 ± 32 GBq/μmol. Product identity and purity were determined by radio-HPLC (30:70 CH3CN/0.1 N ammonium formate) and UV by co-injection with the standard.

In vivo small animal PET/MR imaging study
All three candidate 5-HT1A radioligands, [11C]1, [11C]2, and [11C]3, were tested in dynamic PET studies in rats to further investigate blood-brain barrier (BBB) permeability, regional brain distribution, and tracer kinetics. All experimental procedures were carried out in accordance with the Institutional Animal Care Committee ethical guidelines (Animal Use Protocol # 783).

Animal preparation
Adult male Sprague Dawley rats (500–600 g, 8–12 months old) were anesthetized by isoflurane (5% induction; O2 rate: 2 L/min) and catheterized in the lateral tail vein using a Surfflash Polyurethane IV Catheter 24G × 3/4” (Terumo; Somerset, New Jersey, US). Following insertion, the catheter was flushed with heparinized saline (30 IU/ml, ~ 200 μl). The animal was transferred to the scanner bed in prone position, the head immobilized in a flat skull position for the duration of the acquisition using built in ear and bite bars; the scanner bed temperature was initially set at 40 °C but was subject to alteration based on animals’ body temperature during the experiment. Anesthesia was maintained throughout the PET/MR scanning procedure (isoflurane: 1.5–2%; O2 rate: 1 L/min) and the animals’ body temperature and respiration parameters were closely monitored.

PET/MR acquisition
Imaging studies were conducted on a nanoScan PET/MRI 3 T tomograph (Mediso; Budapest, Hungary). At first, a scout MR was acquired for subsequent PET field of view (FOV) positioning. MR images were used to define anatomical regions of interest
(ROIs) through PET/MRI image co-registration. MR sequences included: material map T1-weighted 2D-gradient echo (GRE, TR 354 ms, TE 3.64) multi-FOV sequence for PET and MR co-registration and PET scatter and attenuation corrections, and T2-weighted 2D-fast spin-echo (FSE, TR 3971 ms, TE 87.5 ms) sequence for co-registration with standard rat brain MR template and atlas of Schwarz et al. (2006), and PET ROI analyses. MR images were acquired either before or after PET imaging.

Three separate imaging experiments were conducted to determine the BBB permeability of $[^{11}C]1$, $[^{11}C]2$, and $[^{11}C]3$, respectively. Concomitantly with a bolus injection of each individual radiotracer (injected radioactivity range for $[^{11}C]1$–$[^{11}C]3$: 14–22 MBq (molar activities at the time of injection for $[^{11}C]1$–$[^{11}C]3$: 75–180 GBq/μmol; mass injected for $[^{11}C]1$–$[^{11}C]3$: 0.15–0.40 nmol/kg), a 60 min emission list mode scan was acquired with an energy window of 400–600 keV.

5-HT$_{1A}$ receptor selectivity of the radiotracer with the most promising brain penetrating properties was further investigated in two separate baseline and pre-treatment (blocking) experiments. A within-subject PET/MR imaging design was employed for baseline and blocking experiments. In the first PET/MR imaging session, brain radiotracer uptake was determined under baseline conditions whereby radiotracer was intravenously administered simultaneously with the start of PET acquisition. The catheter was flushed with heparinized saline (~100 μl) and capped to allow blocker/radiotracer injections for the subsequent pre-treatment experiment. Before the start of the second PET measurement, the animals were infused with a suitable blocking agent intravenously 20 min prior to radiotracer injection and concomitant PET acquisition. To confirm target engagement at 5-HT$_{1A}$ receptor, WAY-100635 maleate (Sigma-Aldrich), a potent 5-HT$_{1A}$ receptor antagonist (2 mg/kg) was infused intravenously 20 min before radiotracer injection. In order to further investigate potential off-target binding at α$_{1}$-adrenergic receptors in vivo, prazosin hydrochloride (Sigma-Aldrich), a potent α$_{1}$-adrenergic receptor antagonist (2 mg/kg) was infused 20 min before radiotracer injection and PET acquisition.

**PET data analyses**

The acquired list mode data was sorted into 33, 3D (3 × 5 s, 3 × 15 s, 3 × 20s, 7 × 60s and 17 × 180 s) true sinograms (ring difference 84). The 3D sinograms were converted in 2D sinograms using fourier-rebinning (Defrise et al. 1997), during which corrections were included for detector geometry and efficiencies, attenuation and scatter, prior to image reconstruction using a 2D–filtered back projection (FBKP) with an Hann filter at a cutoff of 0.50 cm$^{-1}$. A static image of the complete emission acquisition was reconstructed with the manufacturer’s proprietary iterative 3D algorithm (6 subsets, 4 iterations). All image data were corrected for dead-time and decay corrected to the start of acquisition. The dynamic FBKP images were used for the extraction of time-activity curves (TACs). The static iterative image was used for PET and MR co-registration and also for co-registration with standard rat brain MR template and atlas (Schwarz et al. 2006). Image analyses and extraction of regional brain TACs were performed using Amide software (v1.0.4) (Loening and Gambhir 2003). Standardized uptake values (SUV) were calculated by normalizing regional radioactivity for injected radioactivity and body weight of the animal. Regional brain BP were obtained by using simplified reference tissue model (SRTM)
of Lammertsma and Hume (1996), with averaged TACs of left and right cerebellum as the reference. This was performed by using the basis function method (BFM) of Gunn et al. (1997) in the package of Turku PET Centre (https://gitlab.utu.fi/vesoik/tpcclib) (Gunn et al. 1997). Percentages of blocking were calculated by the equation: Blocking\% = 100 x (BP_{blocking} - BP_{baseline})/BP_{baseline}.

**Results and discussion**
In the current study, we report the in vitro pharmacological characterization, radio-syntheses and preliminary in vivo PET imaging of three new 5-HT_{1A} receptor arylpiperazine based ligands in rats.

**In vitro pharmacological characterization**
Results demonstrated nanomolar affinity (K\_i) of the candidate ligands to 5-HT_{1A} receptors (1: 22 nM, 2: 7.7 nM and 3: 5.8 nM) (Fig. 1) and \(\alpha_1\)-adrenergic receptors (1: 129 nM, 2: 46 nM and 3: 23 nM) (Table 1). In vitro data indicate relatively higher binding affinity of compound 3 for 5-HT_{1A} receptors compared to other candidate 5-HT_{1A} receptor ligands and ~ 4-fold selectivity to 5-HT_{1A} receptors over \(\alpha_1\)-adrenergic receptors. Affinity of the candidate ligands for other biogenic amines, receptors, and transporters were low (Ki = 0.1 to >10 \(\mu\)M) (Table 1). Binding affinity ratios of 5-HT_{1A} and \(\alpha_1\)-adrenergic receptors are ~ 6 for compounds 1 and 2 and 4 for compound 3. We did not perform saturation binding studies to determine B_{max} and K_{d} of compounds 1–3 for 5-HT_{1A} and \(\alpha_1\)-adrenergic receptors. Both 5-HT_{1A} and \(\alpha_1\)-adrenergic receptors are highly abundant in hippocampus and cortical brain regions (B_{max}: 100–200 fmol/mg/protein), whereas, 5-HT_{1A} receptors are less expressed in cerebellum, thalamus and striatum (4–10 fmol/mg/protein) compared to \(\alpha_1\)-adrenergic receptors (40–100 fmol/mg/protein) (Burnet et al. 1997; Hall et al. 1997; Kalaria 1989; Khawaja 1995; Kumar et al. 2013; Shimohama et al. 1986). Therefore, given the 4–6-fold high affinity ratios of 5-HT_{1A} vs. \(\alpha_1\)-adrenergic receptors, we expected the \(^{11}\)C-labeled compounds 1–3 to bind preferentially to 5-HT_{1A} receptor site. It should be indicated that previous preliminary pharmacological screening of the current candidate ligands has reported high affinities to other serotonin receptors including 5-HT_{2A} (compounds 1 and 2) and 5-HT_{2C} (compounds 1 and 3) (Fiorino et al. 2012; Fiorino et al. 2016; Fiorino et al. 2017). Compounds 1 and 3 also exhibit high affinity to 5-HT_{1A} receptors (K\_i = 4.68 nM for compound 1 and K\_i = 0.36 nM for compound 3) (Fiorino et al. 2012, Fiorino et al. 2016, Fiorino et al. 2017). Discrepancies between previous reports and the current study are attributed to differences in the binding assay methodology. Previous reports do not provide binding curves for compounds 2 and 3. Also, the curve for compound 1 was derived using only 3-concentrations (1 nM, 10 pM and 0.1 pM) and the reference compound and standard deviation were not stated. Herein, we report results from competitive binding assays of all the three compounds obtained via the NIMH-PDSP and confirm that the ligands have negligible affinity to 5-HT_{2} receptors (Table 1).

**Radiochemistry**
Carbon-11 labelled compounds 1–3 were efficiently prepared by \(^{11}\)C-O-methylation of the corresponding phenolic precursor with \([^{11}\text{C}]\)methyl iodide (\([^{11}\text{C}]\text{CH}_3\text{I}\) as a methylating agent (Fig. 2). Given the susceptibility to in vivo metabolism at the methoxy site, we anticipated that \(^{11}\)C-O-methylation may prevent generation of brain-penetrating
Fig. 1 Binding affinity (Kᵢ) of compounds 1–3 at 5-HT₁A receptors: Competition binding curves for DF-100 (1) (PDSP#50828, top), DF-300 (2) (PDSP#50830, middle) and DF-400 (3) (PDSP#50831, bottom) in the presence of [³H]WAY100635 and 8-OH-DPAT as reference standard.
radiometabolites and thereby would not interfere with subsequent PET image quantification. Radioligands $[^{11}\text{C}]$1–3 were produced in a non-decay corrected RCY of 7–9% (relative $[^{11}\text{C}]\text{CO}_2$ (~37 GBq)) and > 99% RCP using the present conditions in a commercially available and fully-automated $^{11}\text{C}$-methylation synthesis apparatus (GE

Table 1 Binding affinity ($K_i$) of compounds 1–3 for 5-HT$_{1A}$ receptors and other biogenic amines, neurotransmitter receptors, and transporters

| Target          | $K_i$ (nM) | $K_i$ (nM) | $K_i$ (nM) |
|-----------------|-----------|-----------|-----------|
| 5-HT$_{1A}$     | 22        | 7.7       | 5.8       |
| 5-HT1B          | > 10,000  | > 10,000  | > 10,000  |
| 5-HT1E          | > 10,000  | > 10,000  | > 10,000  |
| 5-HT1D          | > 10,000  | > 10,000  | 1176      |
| 5-HT2A          | > 10,000  | > 10,000  | > 10,000  |
| 5-HT2B          | 403       | 516       | 137       |
| 5-HT2C          | > 10,000  | > 10,000  | > 10,000  |
| 5-HT3           | > 10,000  | > 10,000  | > 10,000  |
| 5-HT4           | > 10,000  | > 10,000  | > 10,000  |
| 5-HT5a          | > 10,000  | > 10,000  | 1805      |
| 5-HT6           | > 10,000  | > 10,000  | > 10,000  |
| 5-HT7R          | 76        | 830       | 530       |
| Alpha1A         | 129       | 46        | 23        |
| Alpha1B         | 1080      | 254       | 142       |
| Alpha1D         | 213       | 53        | 19        |
| Alpha 2A        | 453       | > 10,000  | > 10,000  |
| Alpha2B         | 670       | > 10,000  | 2215      |
| Alpha2C         | 835       | > 10,000  | 1984      |
| D2R             | 777       | > 10,000  | 800       |
| D3R             | 369       | 2552      | 133       |
| D4R             | 137       | 88        | 153       |
| D1, D5          | > 10,000  | > 10,000  | > 10,000  |
| DAT             | > 10,000  | > 10,000  | > 10,000  |
| NET             | > 10,000  | > 10,000  | > 10,000  |
| SERT            | > 10,000  | > 10,000  | > 10,000  |
| Adenosine receptors | > 10,000 | > 10,000 | > 10,000 |
| AMPA            | > 10,000  | > 10,000  | > 10,000  |
| Beta Receptors  | > 10,000  | > 10,000  | > 10,000  |
| CB1, CB2        | > 10,000  | > 10,000  | > 10,000  |
| DOR, KOR, MOR   | > 10,000  | > 10,000  | > 10,000  |
| H1-H4           | > 10,000  | > 10,000  | > 10,000  |
| Muscarinic receptors | > 10,000 | > 10,000 | > 10,000 |
| NMDA            | > 10,000  | > 10,000  | > 10,000  |
| NOP             | > 10,000  | > 10,000  | > 10,000  |
| PBR             | > 10,000  | > 10,000  | > 10,000  |
| Sigma 2         | > 10,000  | > 10,000  | > 10,000  |
| Sigma1R         | 520       | > 10,000  | > 10,000  |
TracerLab FX2 C). The overall synthesis time was 37–39 min, and the \( A_m \) was 81–224 GBq/\( \mu \)mol at the end-of-synthesis.

In vivo PET imaging in rats

Brain uptake of \([\textsuperscript{11}C]1\) and \([\textsuperscript{11}C]2\) was negligible (Fig. 3b and c). In contrast, \([\textsuperscript{11}C]3\) exhibited significant brain uptake demonstrating an early peak SUV of 4–5 at \( \sim 1 \) min following radiotracer injection (Fig. 3a). The washout of \([\textsuperscript{11}C]3\) was fast and the regional distribution and retention was different from that expected for 5-HT\(_{1A}\) binding areas based on previously reported neuroimaging studies (Wooten et al. 2011; Saigal et al. 2013). Inability of \([\textsuperscript{11}C]1\) and \([\textsuperscript{11}C]2\) to enter the brain may be attributed to structural modifications that influence efflux transporters and/or metabolizing enzymes (Pike 2009). \([\textsuperscript{11}C]3\) binding was observed in the following rank order: thalamus > prefrontal cortex (medial prefrontal, orbital frontal and anterior cingulate) > striatum > hippocampus and amygdala > occipital cortex > cerebellum (Fig. 3a; see Supplementary Figure 1 for regional BP values estimated with cerebellum as the reference region, see below for discussion).

We further examined the in vivo specificity of \([\textsuperscript{11}C]3\) for 5-HT\(_{1A}\) by conducting a blocking study with WAY100635 (2 mg/kg; IV) that was administered 20 min prior to bolus injection of \([\textsuperscript{11}C]3\). Comparison of TACs derived from baseline and blocking studies revealed decreased uptake of \([\textsuperscript{11}C]3\) in all ROIs (Fig. 4a), including cerebellum, where the TAC showed a slightly faster descending phase but with the peak unchanged,

![Fig. 2](image_url)
suggesting the presence of some specific binding in this imperfect reference region but also that WAY100635 pretreatment did not change tracer delivery to brain. Whole brain BP was estimated to be decreased by 54%, including decreases in hippocampus (57%), anterior cingulate cortex (59%), thalamus (52%), and striatum (39%). Binding in the saliva gland was also decreased by 48%.

Given that thalamus has low 5-HT\textsubscript{1A} receptor concentration, [\textsuperscript{11}C]3 binding to thalamus may represent an off-target binding site for the tracer. In fact, prior in vitro autoradiography studies conducted on rat brain tissue that employed both tritiated and iodinated \(\alpha_1\)-adrenergic antagonist based radioligands revealed high density of \(\alpha_1\)-adrenergic receptors in the thalamus (Jones et al. 1985; Unnerstall et al. 1985). This suggests the presence of significant off-target binding of [\textsuperscript{11}C]3 to \(\alpha_1\)-adrenergic receptors.
in thalamus which we further investigated by pre-treatment blocking studies. Pre-
treatment with a selective $\alpha_1$-adrenergic receptor antagonist, prazosin (2 mg/kg; IV) 20
min prior to radiotracer injection markedly inhibited binding of $[^{11}C]3$ throughout the
brain (Fig. 4b), with regional brain TACs all reduced to nearly overlap with that of
cerebellum. Notably, the peak of the TACs was also markedly decreased, suggesting
that prazosin, as a vasodilator, might have greatly influenced cerebral blood flow and
tracer delivery to the brain. Whole brain BP was estimated to be decreased by 63%, in-
cluding decreases in thalamus (73%), anterior cingulate cortex (69%), hippocampus
(56%), and striatum (34%). Binding in the saliva gland was decreased by 68%.

The cerebellum has been commonly used as the reference tissue for $5-HT_{1A}$ PET
tracers (Saigal et al. 2013; Shrestha et al., 2014). Preliminary PET imaging studies herein
demonstrate lowest uptake of $[^{11}C]3$ in the cerebellum compared to other brain regions
evaluated. To that end, the averaged TAC of left and right cerebellum was used as the

![Fig. 4 Blocking of the uptake of $[^{11}C]3$ in rat brain by WAY-100635 (a) and prazosin (b). Shown are TACs, averaged for left and right brain, (n = 1; solid: baseline; dashed: blocking) in SUV and summed (0–60 min) PET images in coronal, transverse and sagittal planes, respectively, through the thalamus at baseline and under blocking conditions. The three depicted left-half ROIs include thalamus (orange), hippocampus (red) and cerebellum (magenta) for the corresponding color-coded TACs.](image-url)
reference region for the SRTM of Lammertsma and Hume (1996) to derive regional brain BP values. Nevertheless, it is important to note that BP values at baseline and the percentages of blocking might be somewhat underestimated given the small but displaceable binding in the cerebellum. Another limitation of the current investigation is that in vivo metabolite analyses of plasma and brain could not be justified ethically in light of the data. We therefore speculate that non-specific binding revealed in blocking studies may be attributed to non-specific binding of the parent compound to cellular components or accumulation of metabolite, and will be evaluated in future work should promising derivatives of [11C]3 be identified.

Previous studies have reported cross affinity of 5-HT1A ligands for α1-adrenergic receptors (Heimbold et al., 2002; Al Hussainy et al., 2011; Shrestha et al., 2014). [carbonyl-11C]WAY100635 (Ki = 2.2 nM), the most extensively studied 5-HT1A antagonist PET radiotracer also demonstrates nanomolar affinity for α1-adrenergic receptors (Ki = 16.4 nM) (Chemel et al. 2006). While WAY100635 displays ~ 10-fold selectivity for 5-HT1A receptors over α1-adrenergic receptors, in vivo cross selectivity of [carbonyl-11C] WAY100635 with α1-adrenergic receptors has not been reported. In the current study, in vitro data indicate ~ 4-fold selectivity of compound 3 to 5-HT1A receptors over α1-adrenergic receptors which may be insufficient to establish in vivo selectivity for 5-HT1A receptors in the imaging studies. The current results underscore the challenge posed by similarity between the transmembrane domains of 5-HT1A receptors and α1-adrenergic receptor subtypes (Ngo et al., 2013). Taken together, development of ligands with considerably greater fold in vitro selectivity (~ 10 or preferably higher) for the 5-HT1A receptors may be beneficial to avoid PET signal interference from binding to α1-adrenergic receptors.

**Conclusion**

In conclusion, a high yielding radiosynthesis method to produce [11C]3, a potential 5-HT1A antagonist-based radiotracer was achieved. Compound 3 exhibited approximately 4-fold selectivity to 5-HT1A receptors over α1-adrenergic receptors. In vivo imaging experiments, however, demonstrated significant off-target binding, particularly in thalamus, which is attributed to α1-adrenergic receptors based on our blocking studies. Overall, results suggest that apart from thalamic binding, regional distribution of [11C]3 corresponds to that of 5-HT1A receptors. But the off-target binding limits the use of this radiotracer for quantification of 5-HT1A receptors. Nevertheless, results reported herein contribute towards academic knowledge in this field that may support future radiotracer development efforts. Compound 3 represents a promising O-methylated lead candidate which if subjected to structural alterations, may either lead to improved selectivity for 5-HT1A receptors or may assist in the development of the first PET radioligand for α1-adrenergic receptors.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s41181-020-00096-8.

**Abbreviations**

α1: Alpha-1; Am: Molar Activity; BBB: Blood-Brain Barrier; BP: Binding Potential; FBKP: Filtered Back Projection; FOV: Field of View; HPLC: High Performance Liquid Chromatography; 8-OH-DPAT: 8-hydroxy-2-(di-n-propilamino)tetralin;
Acknowledgements
We thank Psychoactive drug screening program of the National Institute of Mental Health (PDSP-NIMH) for competitive binding assays of compounds 1-3.

Authors’ contributions
VN, JT, KD, NV and JSDK: Contributed to the study design of in vivo PET imaging studies in rats; VN, JT, KD, PMB: Coordinated and executed in vivo PET imaging studies in rats; VN, JT, KD and JSDK: Wrote the manuscript; NV, PMB and JIM contributed to manuscript revisions; KD: Established and conducted radiosynthesis procedures; FF, BS, RS, BM, FG, JP: Established and conducted chemical synthesis of radiolabeling precursors. All authors read and approved the final manuscript.

Funding
N.V. thanks National Institute on Ageing of the NIH (R01AG054473), the Azrieli Foundation and the Canada Research Chairs Program for financial support. JIM acknowledges support from The Diane Goldberg Foundation (NYSP/CLIMC). JP thanks National Institute of Drug Abuse grant R21DA041670 for partial support.

Availability of data and materials
All data are included in the manuscript and supplementary information files.

Ethics approval and consent to participate
All animal experimental procedures were carried out in accordance with the Institutional Animal Care Committee ethical guidelines at the Centre for Addiction and Mental Health, Toronto, Ontario.

Consent for publication
Not applicable.

Competing interests
Not applicable.

Author details
1Azrieli Centre for Neuro-Radiochemistry, Research Imaging Centre & Preclinical Imaging, Centre for Addiction and Mental Health, Toronto, Ontario MST-1R8, Canada. 2Department of Pharmacy, University of Naples, Via D. Montesano, 49, 8013 Naples, Italy. 3Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, USA. 4Department of Psychiatry, Columbia University Medical Center, New York, USA. 5Department of Psychiatry, University of Toronto, Toronto, Ontario MST-1R8, Canada.

Received: 11 February 2020 Accepted: 23 April 2020
Published online: 19 May 2020

References
Al Hussainy R, Verbeek J, van der Born D, Braker AH, Leysen JE, Knol RJ, et al. (2011) Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. J Med Chem 54(10):3480–91.

Andree B, Hallidin C, Pike W, Gunn RN, Olsson H, Farde L. The PET radioligand [carbonyl-11C]desmethyl-WAY-100635 binds to 5-HT1A receptors and provides a higher radioactive signal than [carbonyl-11C]WAY-100635 in the human brain. J Nucl Med. 2002;43(3):292–303.

Aznavour N, Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology. 2007;52:695–707.

Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord. 2012;27(1):84–9.

Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083–152.

Burnet NW, Eastwood SL, Harrison PJ. ([5]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int. 1997;30(6):565–74.

Chemel BR, Roth BL, Armbruster B, Watts VI, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology. 2006;188(2):244–51.

Choi JY, Lee M, Jeon TJ, Choi SH, Choi YJ, Lee YK, et al. Determination of optimal acquisition time of [18F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. Appl Radiat Isot. 2014;81:141–5.

Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging. 1997;16(2):145–58.

Drevets WC, Frank E, Price JC, Kuper DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375–87.

Fiorino F, Ciano A, Magli E, Severino B, Convino A, Perissuti E, et al. Synthesis, in vitro and in vivo pharmacological evaluation of serotonergic ligands containing an isonicotinic nucleus. Eur J Med Chem. 2016;110:133–50.
Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Missa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57(2):174–80.

Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12(20):2473–86.

Schwarz AJ, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C, et al. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. NeuroImage. 2006;32(2):538–50.

Shimohama S, Taniguchi T, Fujiwara M, Kanayama M. Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem. 1986;47(4):1295–301.

Shihue CY, Shihue GG, Mozley PD, Kung MP, Zhung ZP, Kim HJ, et al. P-[18F]-MPPF: a potential radioligand for PET studies of S-HT1A receptors in humans. Synapse. 1997;25(2):147–54.

Shrestha S, Liow JS, Lu S, Jerko K, Gladding RL, Svenningsson P, et al. [11C]-CLIM-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to alpha(1) adrenoceptors in brain. J Nucl Med. 2014;55(1):141–6.

Sullivan GM, Quendo MA, Simpson N, Van Heertum RL, Mann JJ, Parsey RV. Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety. Biol Psychiatry. 2005;58(12):947–54.

Unnerstall JR, Fernandez I, Orensanz LM. The alpha-adrenergic receptor: radiohistochemical analysis of functional characteristics and biochemical differences. Pharmacol Biochem Behav. 1985;22(5):859–74.

Weissman-Nanopoulos D, Mach E, Mager L, Demassey Y, Pujol JF. Evidence for the localization of S-HT1A binding sites on serotonin containing neurons in the raphe dorsalis and raphe centralis nuclei of the rat brain. Neurochem Int. 1985;7(6):1061–72.

Wooten DW, Moraino JD, Hillmer AT, Engl JW, Dejesus OJ, Murali D, et al. In vivo kinetics of [F-18]MEFWAY: a comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate. Synapse. 2011;65(7):592–600.

Yasuno F, Zoghbi SS, McCaron JH, Hong J, Ichise M, Brown AK, et al. Quantification of serotonin S-HT1A receptors in monkey brain with [11C](R)-(2)-RWAY. J Nucl Med. 2006;47:510–20.

Zhang X-Y, Yasuno F, Zoghbi SS, Liow JS, Hong J, McCaron JA, et al. Quantification of serotonin S-HT1A receptors in human with [11C](R)-(2)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse. 2007;61:469–77.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.